Translating Stanford discoveries into individualized cancer care
Every day, people living with cancer come to Stanford for help, hope and healing.
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still.
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
CAR-T cells are remarkably effective against blood cancers, but their effect can be transient as the cells become exhausted. Stanford researchers found a way to keep the cells effective in mice with human tumors.
Researchers at Stanford and UCSF slowed the spread of a type of nonsmall cell lung cancer in mice by neutralizing a single protein that would otherwise set off a chain reaction, causing runaway tumor growth.
Anthracyclines can be effective against breast cancer but often have toxic side effects. Stanford researchers used gene expression levels to identify women most likely to benefit from the drugs, regardless of breast cancer type or stage.
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.
